More states are telling HMOs and other health insurers to pick up the tab for pharmaceuticals and other forms of obesity treatment.
As the evidence grows regarding the role that obesity plays in many illnesses, more states are telling HMOs and other health insurers to pick up the tab for pharmaceuticals and other forms of obesity treatment.
According to StateLine,⢠Newtown, PA-based Scott-Levin's tracking system for government legislation and regulation, recent laws have taken effect in:
•Â Georgia, where the governor signed the Morbid Obesity Anti-Discrimination Act, which requires insurers to provide major medical benefits for treatment of morbid obesity.
•Â Indiana, where the governor signed a bill to require health insurers and HMOs to provide coverage for morbid obesity.
•Â Virginia, where the governor signed a bill to require coverage of gastric bypass surgery and "other recognized methods."
According to Scott-Levin, these measures represent just the beginning of this trend. In all, 26 states have recently proposed legislation addressing obesity-related issues.
The legislation is diverse. Some bills would establish commissions to study obesity and its health consequences. Others would regulate existing prescription and over-the-counter therapies for weight loss.
Underlying all this activity is the goal of state health policy-makers to better understand the true cost of obesity. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.